Patents by Inventor Denice Mary Spero

Denice Mary Spero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7312211
    Abstract: Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R2, R3, R4, R6, R8 and Y are defined herein. The compounds are useful for treating autoimmune and other diseases.
    Type: Grant
    Filed: August 26, 2004
    Date of Patent: December 25, 2007
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Denice Mary Spero, Sanxing Sun, Yancey David Ward
  • Patent number: 7279472
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases.
    Type: Grant
    Filed: September 9, 2004
    Date of Patent: October 9, 2007
    Assignee: Boehringer Ingelheim Pharmaceuticals Inc.
    Inventors: Michel Jose Emmanuel, Leah L. Frye, Eugene R. Hickey, Weimin Liu, Tina Marie Morwick, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
  • Patent number: 7265132
    Abstract: Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases.
    Type: Grant
    Filed: September 9, 2004
    Date of Patent: September 4, 2007
    Assignee: Boehringer Ingelheim Pharmaceuticals Inc.
    Inventors: Michel Jose Emmanuel, Leah L. Frye, Eugene R. Hickey, Weimin Liu, Tina Marie Morwick, Denice Mary Spero, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
  • Patent number: 7056915
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases.
    Type: Grant
    Filed: April 24, 2003
    Date of Patent: June 6, 2006
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Michel Jose Emmanuel, Eugene R. Hickey, Weimin Liu, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
  • Patent number: 6982263
    Abstract: Disclosed are novel nitrile compounds of formula (I) further defined herein, which compounds are useful as reversible inhibitors of cysteine proteases such as cathepsin K, S, F, L and B. These compounds are useful for treating diseases and pathological conditions exacerbated by these proteases such as, but not limited to, osteoporosis, rheumatoid arthritis, multiple sclerosis, asthma and other autoimmune diseases, Alzheimer's disease, atherosclerosis. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: January 3, 2006
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Eugene R. Hickey, Younes Bekkali, Usha R. Patel, Denice Mary Spero, David S. Thomson, Erick Richard Roush Young
  • Patent number: 6982272
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: April 24, 2003
    Date of Patent: January 3, 2006
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Michel Jose Emmanuel, Eugene R. Hickey, Weimin Liu, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
  • Patent number: 6936606
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R1, R2, R3, R4, R5, R6, R8, R9 and X are defined herein. The compounds are useful for treating autoimmune and other diseases.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: August 30, 2005
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young, Eugene R. Hickey, Weimin Liu, Usha R. Patel
  • Patent number: 6858627
    Abstract: Compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y, and n are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: February 22, 2005
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Thomas Gilmore, Denice Mary Spero, Hidenori Takahashi, David S. Thomson, Ji Wang
  • Patent number: 6841571
    Abstract: Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R2, R3, R4, R6, R8 and Y are defined herein. The compounds are useful for treating autoimmune and other diseases.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: January 11, 2005
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Denice Mary Spero, Sanxing Sun, Yancey David Ward
  • Patent number: 6756372
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: June 29, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Michel Jose Emmanuel, Weimin Liu, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward
  • Publication number: 20040116455
    Abstract: Compounds of Formula (I) 1
    Type: Application
    Filed: August 12, 2003
    Publication date: June 17, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Thomas Gilmore, Denice Mary Spero, Hidenori Takahashi, David S. Thomson, Ji Wang
  • Publication number: 20040063679
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R1, R2, R3, R4, R5, R6, R8, R9 and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: September 27, 2002
    Publication date: April 1, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals Inc.
    Inventors: Younes Bekkali, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R.R. Young, Eugene R. Hickey, Weimin Liu, Usha R. Patel
  • Publication number: 20040053921
    Abstract: Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R2, R3, R4, R6, R8 and Y are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: October 24, 2002
    Publication date: March 18, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Denice Mary Spero, Sanxing Sun, Yancey David Ward
  • Publication number: 20030225270
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: April 24, 2003
    Publication date: December 4, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Michel Jose Emmanuel, Eugene R. Hickey, Weimin Liu, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
  • Publication number: 20030225271
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: April 24, 2003
    Publication date: December 4, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Michel Jose Emmanuel, Eugene R. Hickey, Weimin Liu, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
  • Publication number: 20030119827
    Abstract: Disclosed are novel nitrile compounds of formula (I) further defined herein, which compounds are useful as reversible inhibitors of cysteine proteases such as cathepsin K, S, F, L and B. These compounds are useful for treating diseases and pathological conditions exacerbated by these proteases such as, but not limited to, osteoporosis, rheumatoid arthritis, multiple sclerosis, asthma and other autoimmune diseases, Alzheimer's disease, atherosclerosis. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: June 4, 2002
    Publication date: June 26, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Eugene R. Hickey, Younes Bekkali, Usha R. Patel, Denice Mary Spero, David S. Thomson, Erick Richard Roush Young
  • Patent number: 6420364
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: July 16, 2002
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Michel Jose Emmanuel, Leah L. Frye, Eugene R. Hickey, Weimin Liu, Tina Marie Morwick, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
  • Publication number: 20020058809
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: November 2, 2001
    Publication date: May 16, 2002
    Inventors: Michel Jose Emmanuel, Eugene R. Hickey, Weimin Liu, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
  • Publication number: 20010041700
    Abstract: Disclosed are novel succinate derivative compounds of the formula (I)/(Ia): 1
    Type: Application
    Filed: May 22, 2001
    Publication date: November 15, 2001
    Inventors: Younes Bekkali, Rajashehar Betageri, Michel Jose Emmanuel, Eugene Richard Hickey, Weimin Liu, Usha R. Patel, Denice Mary Spero, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
  • Patent number: 6313117
    Abstract: Disclosed are novel succinate derivative compounds of the formula(I)/(Ia): wherein R1, R2, R3, R4, R5, R6, R7, X and A are defined herein. The compounds are useful as inhibitors of cysteine proteases. Also disclosed are methods of using and methods of making such compounds.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: November 6, 2001
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Rajashehar Betageri, Michel Jose Emmanuel, Eugene Richard Hickey, Weimin Liu, Usha R. Patel, Denice Mary Spero, David S. Thomson, Yancey David Ward, Erick Richard Roush Young, Sanxing Sun